CHF10067

The purpose of this study is to assess the safety of CHF10067 (the study drug) and any side effects that might be associated with it. In addition, the study will evaluate how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug will also be evaluated. The study may also evaluate the effect of the study drug on the level of a certain protein in the body.
Chiesi is conducting this study on patients affected by idiopathic pulmonary fibrosis (IPF, a lung disease).
Chiesi is doing this study to establish the doses suitable for future studies.